Belite Bio Inc (BLTE) shares gained more than 3% on Monday after the company unveiled additional secondary endpoint data from its ongoing Phase 3 DRAGON trial for its drug candidate tinlarebant, which targets Stargardt disease type 1 (STGD1).

STGD1 is the most common inherited macular dystrophy, affecting both children and adults. It's caused by mutations in the ABCA4 gene, which is only active in the retina. When that gene is broken, it leads to a steady buildup of toxic substances called bisretinoids. Over time, that accumulation kills retinal cells and causes progressive loss of central vision.

Divergence in Toxic Accumulation

The new data focused on a key metric called quantitative autofluorescence (qAF), which tracks the dangerous buildup of bisretinoids in the retina. After 25 months, patients who received tinlarebant showed qAF levels that were either stable or had decreased by about 2% from their starting point. In contrast, patients in the placebo group saw their qAF levels jump by roughly 20% from baseline.

That's a pretty stark divergence, and it suggests tinlarebant is doing what it's supposed to do: stopping the toxic accumulation that drives vision loss.

Primary Endpoint Already Hit

The new data builds on earlier results from the same trial. The Phase 3 DRAGON study enrolled 104 patients across 11 countries, with patients randomly assigned to either tinlarebant or placebo in a 2-to-1 ratio.

The trial had already met its primary endpoint: tinlarebant reduced the growth rate of retinal lesions by 35.7% compared to placebo, a result that was both clinically meaningful and statistically significant. That was measured using a technique called fundus autofluorescence imaging, which tracks areas of definitely decreased autofluorescence (DDAF).

The drug also appeared to be well-tolerated, which is always good news for a potential treatment.

What This Means for Patients

Stargardt disease is a rare genetic condition with no approved treatments currently on the market. If tinlarebant continues to show positive results, it could become the first therapy available for patients who currently have no options to slow the progression of their vision loss.

Belite Bio is also pursuing a rolling submission of a New Drug Application to the FDA, which suggests the company is moving quickly to bring this drug to market if the data holds up.

BLTE Stock Price Activity: Belite Bio shares were up 3.11% at $154.74 at the time of publication on Monday, according to market data.